AAOS Guidelines for VTE: Elective Total Hip with DVT History
Key Takeaway
This topic focuses on AAOS Guidelines for VTE: Elective Total Hip with DVT History, For patients undergoing **elective total hip** arthroplasty with a history of deep vein thrombosis (DVT), the 2011 AAOS guideline recommends receiving both pharmacologic and mechanical prophylaxis postoperatively. A prior DVT history increases the risk of venous thromboembolic disease but does not make proceeding with surgery unsafe or require cancellation.
A 68-year-old patient is scheduled for elective primary total hip arthroplasty. During your preoperative consultation, they disclose a history of an unprovoked deep vein thrombosis (DVT) in the left lower extremity three years ago, treated with a six-month course of anticoagulation. How would you approach the venous thromboembolism (VTE) risk assessment and prophylactic planning for this patient?
Candidate: I would classify this patient as high-risk given their prior history of VTE. I would perform a comprehensive assessment including their comorbidities, BMI, and a formal bleeding risk screen. I would favor using a robust pharmacological agent like an LMWH or a DOAC for an extended duration of up to 35 days, combined with mechanical prophylaxis using sequential compression devices. I would also engage in shared decision-making regarding the risks of thrombosis versus bleeding.
The candidate fails to acknowledge the difference between "routine" and "high-risk" protocols. They might suggest standard 10-14 day aspirin-only prophylaxis without considering that an unprovoked history of DVT warrants intensification. Furthermore, they often forget to mention the preoperative review of any pre-existing hematology workup for thrombophilias.
The perfect answer is structured using the "Three Pillars of Prophylaxis": 1. Risk Stratification: Acknowledge the patient is "high-risk" due to the prior unprovoked DVT. 2. Individualized Planning: Recommend a multimodal approach combining mechanical prophylaxis (SCDs/IPCs) with potent pharmacological agents (LMWH or DOACs). 3. Clinical Logic: Emphasize AAOS recommendations for extended prophylaxis (up to 35 days) for this high-risk cohort, while explicitly mentioning the need for a hematology/vascular review if there are unresolved questions regarding potential underlying hypercoagulable states (thrombophilias).
During the postoperative period, the patient develops a symptomatic, ultrasound-confirmed deep vein thrombosis in the distal calf. They are currently on a DOAC. What are the key elements of your management strategy?
Candidate: I would immediately evaluate the patient for signs of pulmonary embolism. Regarding the DVT, I would ensure therapeutic anticoagulation is optimized. If the current agent is a DOAC, I would verify compliance, renal dosing, and potential drug interactions. If the thrombus is progressing, I would consider a hematology consult for potential management changes or further investigation into hypercoagulability.
Ignoring the "why." Candidates often jump to "give heparin" without investigating why the patient failed a standard prophylactic dose of a DOAC. They also fail to mention the importance of verifying drug-drug interactions (e.g., with common post-op pain medications or antibiotics) or renal function.
The candidate demonstrates a systematic approach: 1. PE Assessment: Clear the airway, assess breathing, and clinical signs of instability. 2. Treatment Audit: Evaluate "Compliance, Clearance, and Consistency"—are they taking it? Is their renal function consistent with the dose? 3. Hematology Collaboration: For a "breakthrough" VTE while on therapy, involve a hematologist for a formal hypercoagulability workup (if not done) and potential escalation/switching of the agent. 4. Mobilization: Emphasize that once therapeutically anticoagulated, early mobilization is encouraged to prevent further stasis.
